Bo-Jung Chen

Dr. Bo-Jung Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
YSYao-An Shen
Yao-An Shen
CCChang-Cyuan Chen
Chang-Cyuan Chen
BCBo-Jung Chen
Bo-Jung Chen
YWYu-Ting Wu
Yu-Ting Wu
JJJiun-Ru Juan
Jiun-Ru Juan
YWYau-Huei Wei
Yau-Huei Wei
Cancer stem cells (CSCs) are heterogeneous cells with stem cell-like properties that are responsible for therapeutic resistance, recurrence, and metastasis, and are the major cause for cancer treatment failure. Since CSCs have distinct metabolic characteristics that plays an important role in cancer development and progression, targeting metabolic pathways of CSCs appears to be a promising therapeutic approach for cancer treatment. Here we classify and discuss the unique metabolisms that CSCs rely on for energy production and survival, including mitochondrial respiration, glycolysis, glutaminolysis, and fatty acid metabolism. Because of metabolic plasticity, CSCs can switch between these metabolisms to acquire energy for tumor progression in different microenvironments compare to the rest of tumor bulk. Thus, we highlight the specific conditions and factors that promote or suppress CSCs properties to portray distinct metabolic phenotypes that attribute to CSCs in common cancers. Identification and characterization of the features in these metabolisms can offer new anticancer opportunities and improve the prognosis of cancer. However, the therapeutic window of metabolic inhibitors used alone or in combination may be rather narrow due to cytotoxicity to normal cells. In this review, we present current findings of potential targets in these four metabolic pathways for the development of more effective and alternative strategies to eradicate CSCs and treat cancer more effectively in the future.

15 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
CLChih-Yi Liu
Chih-Yi Liu
BCBo-Jung Chen
Bo-Jung Chen
SCShih-Sung Chuang
Shih-Sung Chuang
Primary effusion lymphoma (PEL) is defined by the WHO classification as a large B-cell neoplasm without detectable tumor masses. It is universally associated with HHV8, with most cases occurring in the setting of immunodeficiency such as HIV infection, and a poor prognosis. Morphologically, the neoplastic cells range from immunoblastic, plasmablastic, to anaplastic; and phenotypically, most cases express plasma cell but not B-cell markers, i.e., plasmablastic. During the past decade, primary HHV8-negative effusion lymphoma has been reported. Such cases were considered in the WHO classification scheme as effusion-based lymphoma. We performed a systemic review of 167 HHV8-negative effusion lymphomas from the literature and found that only 42% were associated with a fluid overload state, and with low rates of HIV (6%) or EBV (21%) infection. Furthermore, most patients are old (or immunosenescent) with underlying medical conditions/comorbidities, most neoplasms are of B-cell phenotype, and the outcome is more favorable than that of HHV8-positive PEL. These distinctive findings supported our prior proposal of designating these HHV8-negative cases as type II PEL, in contrast to the classic or type I PEL as defined by the WHO. Furthermore, we propose an algorithmic approach for the diagnosis of PEL and its mimickers.


29 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JWJinn Li Wang
Jinn Li Wang
WLWei-Jiunn Lee
Wei-Jiunn Lee
CFChia-Lang Fang
Chia-Lang Fang
HHHan-Lin Hsu
Han-Lin Hsu
BCBo-Jung Chen
Bo-Jung Chen
HLHsingjin Eugene Liu
Hsingjin Eugene Liu
High-risk human papillomavirus (HPV) infections and epidermal growth factor receptor (EGFR) expression have been reported to be associated with more favorable survival outcomes in lung adenocarcinoma patients. In this study, we utilized transfected HPV 16E5/16E6/16E7 H292 cells to investigate the mechanism of HPV oncoproteins interfering with EGFR nuclear trafficking related to a better response to cisplatin. Furthermore, we correlated HPV 16E6/18E6 expression and differentially localized EGFR expression with the clinical association and survival impact in lung adenocarcinoma patients. Our results found significantly higher phosphorylated nuclear EGFR expression upon epidermal growth factor stimulus and better responses to cisplatin in transfected HPV 16E5/16E6/16E7 NCI-H292 cells and xenograft animal models. Our data were compatible with clinical results of a high correlation of HPV 16E6/18E6 and EGFR expression in non-small cell lung cancer tissues and the synergistic effects of both with the best survival prognosis in a lung adenocarcinoma cohort, especially in patients with older age, no brain metastasis, smoking history, and wild-type EGFR status. Cumulatively, our study supports HPV 16E5/16E6/16E7 oncoproteins interfering with EGFR nuclear trafficking, resulting in increased sensitivity to cisplatin. HPV 16E6/18E6 and EGFR expression serve as good prognostic factors in lung adenocarcinoma patients.

7 November 2022 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
CCChien-Ta Chiang
Chien-Ta Chiang
SCShih-Sung Chuang
Shih-Sung Chuang
HLHsuen-Fu Lin
Hsuen-Fu Lin
WLWei-Hsuan Li
Wei-Hsuan Li
YCYing-Yi Chiang
Ying-Yi Chiang
BCBo-Jung Chen
Bo-Jung Chen
Primary cutaneous T-cell lymphoma is distinct from nodal T-cell lymphoma clinically and pathologically. Recently, primary cutaneous follicular helper T-cell lymphoma (PC-TFHL) has been described as a peripheral T-cell lymphoma with T-follicular helper (TFH) cell phenotype. PC-TFHL usually presents as multiple plaques and nodules of skin with an indolent clinical course, but without association with Epstein–Barr virus. In this article, we report 2 rare cases of PC-TFHL which are Epstein–Barr virus–positive and with an aggressive clinical course. We discuss the challenges in the differential diagnoses, particularly with primary cutaneous extranodal NK/T-cell lymphoma, and nodal T-cell lymphoma of TFH origin with secondary cutaneous involvement.

1 October 2021 in Dermatologica Sinica
Verified
Journal Article
Open access
YMYi-Ning Mao
Yi-Ning Mao
JJJie-Yang Jhuang
Jie-Yang Jhuang
BCBo-Jung Chen
Bo-Jung Chen
YWYu-Hung Wu
Yu-Hung Wu
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society